Cerebrolysin

What it is

Cerebrolysin is not a single peptide. It is a complex mixture produced by standardized enzymatic hydrolysis of purified porcine brain tissue, yielding a solution of free amino acids together with low-molecular-weight peptides (below approximately 10 kDa). The manufacturer (Ever Neuro Pharma, based in Austria) describes the active fraction as a defined blend of neurotrophic peptide fragments analogous to endogenous brain-derived growth factors.

The commercial product is supplied as a clear amber solution in ampoules, given by intramuscular or intravenous infusion. The standard concentration is 215.2 mg of peptide preparation per 1 mL.

History

Cerebrolysin has been on the market for an unusually long time. Early formulations trace back to the late 1940s in Austria, with continuous reformulation and standardization over subsequent decades. The current manufacturer, Ever Neuro Pharma (formerly Ebewe), brought the product into modern pharmaceutical regulation in Austria and registered it across more than fifty countries — most heavily in Russia, China, India, Mexico, and across Eastern Europe and Southeast Asia.

The modern controlled-trial program includes the CARS trial in post-stroke recovery (Muresanu et al., Stroke, 2016), the CAPTAIN II trial in moderate-to-severe traumatic brain injury (Muresanu et al., Neurological Sciences, 2020), and the vascular dementia trial by Guekht and colleagues (2011). Several Cochrane reviews have examined the evidence base; the latest concluded that effects on stroke recovery are modest and that quality varies across older studies.

Regulatory status

Cerebrolysin is approved in 50+ countries for ischemic stroke, vascular and Alzheimer's dementia, and traumatic brain injury. It is dispensed by prescription and given by clinicians, typically as a course of daily infusions over 10 to 21 days.

It has never been approved by the FDA or through the EMA centralized procedure. National marketing authorizations within Europe exist in Austria and some Eastern European countries. In the United States and the United Kingdom, Cerebrolysin is not legally available as a drug, and importation for personal use is restricted by the relevant agencies.

How researchers describe its action

Because Cerebrolysin is a mixture rather than a defined molecular entity, mechanism-of-action papers describe pleiotropic effects rather than a single receptor target. The manufacturer's mechanism narrative, supported by preclinical and translational papers, includes:

1. Neurotrophic mimicry. The peptide fragments are described as functionally analogous to endogenous neurotrophic factors such as BDNF, GDNF, NGF, and CNTF.
2. Anti-apoptotic signaling. Preclinical work reports reduction of caspase activation and stabilization of mitochondrial function under ischemic stress.
3. Modulation of amyloid processing. Animal and cell-culture studies in Alzheimer models describe reduced amyloid-beta deposition and altered APP processing.
4. Neurogenesis and synaptic plasticity. Effects on hippocampal neurogenesis have been reported in rodent stroke and aging models.

Because the input material is purified porcine brain and the active components are not fully defined, batch-to-batch consistency depends on the manufacturer's standardization process.

Half-life and dosing intervals

Cerebrolysin is a mixture, so a single half-life is not defined. The manufacturer's pharmacokinetic data describe rapid clearance of individual peptide components within minutes to hours of infusion. The clinical effect, as with other neurotrophic-pathway interventions, is hypothesized to outlast plasma exposure due to downstream signaling.

Dosing in the controlled trials varied by indication:

• Acute ischemic stroke (CARS): 30 mL daily IV infusion for 21 days, started within 72 hours of stroke.
• Vascular dementia (Guekht 2011): 20 mL daily IV infusion for 20 days, repeated as treatment courses.
• Traumatic brain injury (CAPTAIN II): Up to 50 mL daily IV infusion for 10 days, followed by additional courses.

These are the doses tested in the randomized trials. The peptide preparation is delivered as a slow infusion in saline; faster bolus administration is not part of the approved regimens.

Reconstitution example

Cerebrolysin is supplied as a ready-to-use sterile solution in 1 mL, 2 mL, 5 mL, 10 mL, 20 mL, and 30 mL ampoules at 215.2 mg/mL. It is not lyophilized and does not require reconstitution. For intravenous administration the manufacturer specifies dilution in normal saline, lactated Ringer's, or 5% dextrose, with infusion typically over 15 to 60 minutes depending on volume.

There is no validated route for self-administration; the labeled use is clinical, with infusions performed under medical supervision.

What to know

• Mixture, not a single peptide. Cerebrolysin is a hydrolysate; batch consistency depends on the manufacturer's process.
• Effect sizes are modest. The CARS trial showed modest improvement in upper-extremity motor function at day 90; Cochrane reviews note that broader benefits in stroke and dementia are small and that older trials varied in quality.
• Safety profile. Decades of post-marketing use have not generated major safety signals. Local injection-site reactions and rare hypersensitivity are the most commonly reported adverse events.
• Not legally available in the U.S., U.K., Canada, Australia, or France; importation for personal use is restricted.
• Storage. Refrigerate the ampoules per the package insert. Once opened, the solution should be used immediately or discarded.
• Porcine origin. The peptide preparation is derived from pig brain, which is a consideration for individuals avoiding animal-origin pharmaceuticals on religious or dietary grounds.